Cancer Epidemiology
Volume 34, Issue 2 , Pages 178-183 , April 2010

CYP2C9 genotype does not affect risk of tobacco-related cancer in the general population

  • Diljit Kaur-Knudsen

      Affiliations

    • Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark
    • Department of Diagnostic Sciences, Faculty of Health Sciences, University of Copenhagen, Denmark
    • ,
  • Børge Grønne Nordestgaard

      Affiliations

    • Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark
    • Department of Diagnostic Sciences, Faculty of Health Sciences, University of Copenhagen, Denmark
    • The Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, Denmark
    • ,
  • Stig Egil Bojesen

      Affiliations

    • Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark
    • Department of Diagnostic Sciences, Faculty of Health Sciences, University of Copenhagen, Denmark
    • The Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, Denmark
    • Corresponding Author InformationCorresponding author at: Department of Clinical Biochemistry, 54M1, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Tel.: +45 4488 3843; fax: +45 4488 3311.

,Accepted 6 January 2010.

References 

  1. The health consequences of smoking. A report of the Surgeon General, Office of the Surgeon General (2004), p. 1–921.
  2. Ding YS, Ashley DL, Watson CH. Determination of 10 carcinogenic polycyclic aromatic hydrocarbons in mainstream cigarette smoke. J Agric Food Chem. 2007;55(15):5966–5973
  3. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360(9340):1155–1162
  4. Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet. 2006;21(4):257–276
  5. Shou M, Krausz KW, Gonzalez FJ, Gelboin HV. Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450. Arch Biochem Biophys. 1996;328(1):201–207
  6. Boffetta P, Jourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control. 1997;8(3):444–472
  7. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54(10):1257–1270
  8. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996;6(5):429–439
  9. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349–355
  10. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–764
  11. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999–1008
  12. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308
  13. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12000 men and women from The Copenhagen City Heart Study. Eur Heart J. 2002;23(8):620–626
  14. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524–2532
  15. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897–1908
  16. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27(13):2217–2224
  17. Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Integrin beta3 Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst. 2003;95(15):1150–1157
  18. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, Nordestgaard BG. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 2009;27(4):572–578
  19. Lee J, Nordestgaard BG, Dahl M. Elevated ACE activity is not associated with asthma, COPD, and COPD co-morbidity. Respir Med. 2009;103(9):1286–1292
  20. London SJ, Daly AK, Leathart JB, Navidi WC, Idle JR. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics. 1996;6(6):527–533
  21. London SJ, Sullivan-Klose T, Daly AK, Idle JR. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics. 1997;7(5):401–404
  22. Garcia-Martin E, Martinez C, Ladero JM, Gamito FJ, Rodriguez-Lescure A, Agundez JA. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Lett. 2002;180(1):41–46
  23. Fortuny J, Kogevinas M, Garcia-Closas M, Real FX, Tardon A, Garcia-Closas R, et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1696–1702
  24. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, Harper PA. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3098–3107
  25. Martinez C, Garcia-Martin E, Ladero JM, Sastre J, Garcia-Gamito F, az-Rubio M, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis. 2001;22(8):1323–1326
  26. McGreavey LE, Turner F, Smith G, Boylan K, Timothy BD, Forman D, et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics. 2005;15(10):713–721
  27. Siemes C, Eijgelsheim M, Dieleman JP, van Schaik RH, Uitterlinden AG, van Duijn CM, et al. No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype. Neth J Med. 2009;67(4):134–141
  28. Tranah GJ, Chan AT, Giovannucci E, Ma J, Fuchs C, Hunter DJ. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses’ Health Study and the Physicians’. Health Study Mol Carcinog. 2005;44(1):21–30

PII: S1877-7821(10)00006-8

doi: 10.1016/j.canep.2010.01.003

Cancer Epidemiology
Volume 34, Issue 2 , Pages 178-183 , April 2010

Article Tools